169 related articles for article (PubMed ID: 34845005)
1. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.
Ma Y; Liu N; Wang Y; Zeng J; Hu YY; Hao W; Shi H; Zhu P; Lv J; Fan W; Wang X
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34845005
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
4. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
5. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB; Machiraju D; Kälber KA; Hassel JC
Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
[TBL] [Abstract][Full Text] [Related]
7. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies.
Tsimafeyeu I; Volkova M; Alekseeva G; Berkut M; Nosov A; Myslevtsev I; Andrianov A; Semenov A; Borisov P; Zukov R; Goutnik V; Savchuk S; Dengina N; Mitin T
J Hematol Oncol; 2021 Nov; 14(1):192. PubMed ID: 34774086
[TBL] [Abstract][Full Text] [Related]
8. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
9. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
14. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
[TBL] [Abstract][Full Text] [Related]
15. Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine.
Cancer Discov; 2021 Sep; 11(9):2122. PubMed ID: 34272229
[TBL] [Abstract][Full Text] [Related]
16. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.
Läubli H; Balmelli C; Kaufmann L; Stanczak M; Syedbasha M; Vogt D; Hertig A; Müller B; Gautschi O; Stenner F; Zippelius A; Egli A; Rothschild SI
J Immunother Cancer; 2018 May; 6(1):40. PubMed ID: 29789020
[TBL] [Abstract][Full Text] [Related]
18. Nomogram for prediction of fatal outcome in patients with severe COVID-19: a multicenter study.
Yang Y; Zhu XF; Huang J; Chen C; Zheng Y; He W; Zhao LH; Gao Q; Huang XX; Fu LJ; Zhang Y; Chang YQ; Zhang HJ; Lu ZJ
Mil Med Res; 2021 Mar; 8(1):21. PubMed ID: 33731184
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates.
Lodde GC; Fiedler M; Dittmer U; Placke JM; Jansen P; Becker JC; Zimmer L; Livingstone E; Schadendorf D; Sondermann W; Ugurel S
Front Oncol; 2022; 12():879876. PubMed ID: 36091146
[TBL] [Abstract][Full Text] [Related]
20. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]